Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a ...

HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to ...

Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the ...

Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.

When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing ...

Only 66% of FDA-approved biosimilars launched, with Humira & Enbrel facing limited competition despite biosimilars priced ...

AbbVie CEO Rob Michael said the company will invest $10 billion in the US over the next decade, as the threat of ...

ALX On­col­o­gy’s ef­forts to progress a CD47 com­bo hit a ma­jor speed bump. The com­pa­ny said Fri­day that two tri­als ...

Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies ...

The grow­ing drug dis­count pro­gram for low-in­come Amer­i­cans, known as the 340B pro­gram, has “trans­paren­cy and ...

Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.

Sanofi reports Q1 growth with Altuviiio sales doubling to €251M and Dupixent reaching €3.5B; company terminates two cancer ...